explore -WSS

explore

author：explore 2025-09-27 13:02:55 - browse：1137

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： With measles on the rise, a personal story of a devastating disease

explore

WSS

Venture capitalist Bob Kocher on the state of digital health

Solving academic medical centers' existential crisis

Lab trade group sues FDA to halt regulation of lab

Focused ultrasound for uterine fibroids: an uphill battle

Dark money group runs ads on China biotech bill

Criminal prosecution for violating HIPAA: an emerging threat

knowledge

explore

hotspot

Moonlake's readout produced a cash windfall. Risks remain

With measles on the rise, a personal story of a devastating disease

Trump demands the U.S. pay no more for drugs than other countries … again

Data integrity in scientific journals requires "effort" by publishers, institutions

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

How to save PrEP access — and even expand it

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Trump demands the U.S. pay no more for drugs than other countries … again

Childbirth

leisure time

Startling documents reveal new facets of Sacklers' opioid empire

Average age of first period drops to 11.9 years, study shows

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Average age of first period drops to 11.9 years, study shows

Adam's Biotech Scorecard: Do Sarepta's exon

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

leisure time

explore

leisure time

explore